We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 35

Apotex loses the war in Canada and the battle in England: UK courts rely on Canadian decision to find Apotex acting unlawfully in cCnada has consequences in eErope
  • Gowling WLG
  • United Kingdom, Canada
  • October 13 2011

Servier developed perindopril erbumine (“perindopril”) which is a successful long lasting ACE inhibitor sold under the trade-mark COVERSYL.


Data protection in Canada: too much? Too little?
  • Gowling WLG
  • Canada
  • June 28 2011

Prior to the enactment in 2006 of the amendments to section C.08.004.1 of the Food and Drugs Regulations (Data Protection Regulations), Canada did not have an effective regime of data protection exclusivity.


Maker of VODKAT fails to convince Court of Appeal that extended passing off is now too broad
  • Gowling WLG
  • United Kingdom
  • August 26 2010

The Court of Appeal has upheld the judgment of Arnold J in January that Intercontinental Brands (ICB) passed off its VODKAT product as vodka and thereby caused damage to Diageo, manufacturer of the SMIRNOFF brand of vodka.


Health Canada releases final guidance on biosimilars
  • Gowling WLG
  • Canada
  • March 25 2010

On March 8, 2010, Health Canada released its final guidance documents relating to the approval pathway for subsequent entry biologics (SEBs) in Canada.


Quebec applies California standards to greenhouse gas emissions from motor vehicles
  • Gowling WLG
  • Canada
  • March 5 2010

Québec's Regulation in respect of greenhouse gas emissions from motor vehicles, whose standards are equivalent to those in force in California, came into effect in on January 14, 2010.


Generic manufacturers in Europe seek regulatory changes
  • Gowling WLG
  • European Union
  • February 12 2010

The European Generic Medicines Association (EGA) is advocating for changes to regulatory framework of the European Union with respect to the marketing of generics and biosimilars in the European Union.


Tactical trade marks and bad faith bunnies?
  • Gowling WLG
  • Austria, United Kingdom, European Union
  • August 27 2009

The European Court of Justice (ECJ) had provided guidance to the national Austrian court as to the factors to be considered when determining whether a registration applied for in the knowledge that other very similar marks were being used in the Community is to be considered as having been made in bad faith.


What’s your patent worth? A quick guide to estimating a patent’s market value
  • Gowling WLG
  • Global
  • August 15 2009

Patents, which bestow a right to exclude others from making, using and selling an invention, are a form of intellectual property.


Canada v. Pharmascience
  • Gowling WLG
  • Canada
  • July 27 2009

The Court of Appeal upheld the decision of the trial judge holding that the generic company was not required to address the patents listed on the patent register against submissions filed after it had purchased its comparator drug.


Proposed changes to Common Drug Review process
  • Gowling WLG
  • Canada
  • December 16 2008

Proposed changes to the Common Drug Review (CDR) process have been published for consultation purposes.